Orforglipron
Orforglipron is Eli Lilly’s oral, non-peptide GLP-1 receptor agonist now in Phase 3 trials; the small community conversation that exists centers on weight management and appetite control. Early clinician sources cite 6 mg orally each day on a continuous schedule, though no consistent community dosing pattern has emerged because the compound remains investigational. The evidence base is thinner than online discussion suggests: most exploratory indications lack posted results, and the entire captured community corpus rests on just seven user reports with mixed outcomes.
Research Evidence
Evidence shape
The strongest evidence sits in obesity and type 2 diabetes, the two indications where the strongest trials have posted blinded results. Across forty-six registered trials covering twelve distinct conditions, only three blinded studies have reported data, and the remainder of the program is thin or exploratory. Six conditions in the long tail—including osteoarthritis, peripheral arterial disease, stress urinary incontinence, and obstructive sleep apnea—are each represented by a single trial with no results posted.
Anecdotal efficacy
Side effects
Clinical research side effects
Anecdotal side effects
Price
price offers can be sorted by column
Dosing & Protocol
How Orforglipron is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
- Frequency
- daily
- Timing
- unspecified
- Route
- oral
- Cycle
- unspecified
32 completed trials identified; trial dosing not reliably extracted from registry data.
- Frequency
- daily
- Timing
- unspecified
- Route
- oral
- Cycle
- unspecified
Clinician protocols dose 800 µg daily oral (1 source).
- Frequency
- unspecified
- Route
- oral
Community reports indicate use for weight management and appetite control, with 1 of 3 reports being positive. Specific dose figures are not available from anecdotal sources at this time.
Peptide Deep Dive
Peptide Deep Dive is not projected for this peptide yet.
Regulatory safety notes
- • Acute Pancreatitis: Has been observed in patients treated with GLP-1 receptor agonists, including FOUNDAYO. Discontinue if pancreatitis is suspected.
- • Severe Gastrointestinal Reactions: Use has been associated with gastrointestinal adverse reactions, sometimes severe. FOUNDAYO is not recommended in patients with severe gastroparesis.
- • Acute Kidney Injury Due to Volume Depletion: Monitor renal function in patients reporting adverse reactions that could lead to volume depletion.
- • Hypoglycemia: Concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing the dosage of insulin or insulin secretagogue may be necessary. Inform all patients of the risk of hypoglycemi…
- • Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with GLP-1 receptor agonists. If suspected, advise the patient to promptly seek medical attention and discontinue FOUNDAYO.
- • Diabetic Retinopathy Complications in Patients with Type 2 Diabetes: Has not been studied in patients with diabetic retinopathy and/or macular edema requiring acute treatment. Monitor patients with a history of diabetic retinopathy for progression.
- • Acute Gallbladder Disease : Has been reported in clinical trials. If cholecystitis is suspected, gallbladder studies and clinical follow-up are indicated.
- • Pulmonary Aspiration During General Anesthesia and Deep Sedation: Has been reported in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures. Instruct patients to inform healthcare providers of any planned surgeries or procedu…
- • FOUNDAYO is contraindicated in
- • patients with: A personal or family history of MTC or in
- • patients with MEN 2 [see Warnings and Precautions (5.1) ] . Known serious hypersensitivity to orforglipron or any of the excipients in FOUNDAYO. Serious hypersensitivity reactions, including anaphylaxis and angioedema,…
- • patients with MEN 2 Known serious hypersensitivity to orforglipron or any of the excipients in FOUNDAYO
- • Inhibitors: The maximum dosage of FOUNDAYO is 9 mg once daily when used concomitantly with a strong CYP3A4 inhibitor. Avoid concomitant use with strong CYP3A4 inhibitors that also inhibit OATP1B. (7.1) CYP3A4
- • Inducers: Avoid concomitant use with strong CYP3A4 inducers. Monitor FOUNDAYO effectiveness and escalate dosage as needed when used concomitantly with moderate CYP3A4 inducers. (7.1)
- • Simvastatin: Do not exceed simvastatin 20 mg once daily when used concomitantly with FOUNDAYO. (7.2) FOUNDAYO delays gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. (7.3)
Peptide feedback
0 forum repliesLive community discussion for Orforglipron, shown here in the site layout and continued on the TVR forum.
No peptide feedback yet
Start the peptide feedback thread on the TVR forum.